Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.57 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.57 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.52 |
| ▸ | FDPS | P14324 | 9/20 | 0.50 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.48 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.48 |
| ▸ | S1PR2 | O95136 | 4/20 | 0.47 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.47 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7785400 | 0.82 | GGPS1 (0.53) | LPAR3LPAR2GGPS1FDPSSMPD1 | |
| SCHEMBL27704949 | 0.78 | TSHR (0.50) | GGPS1FDPS | |
| SCHEMBL321313 | 0.77 | GRM4 (0.48) | LPAR3LPAR2FDPSS1PR2S1PR4 | |
| Ammonia Solution, Strong SCHEMBL2210353 | 0.76 | TSHR (0.47) | GGPS1FDPS | |
| Ammonia Solution, Strong SCHEMBL2315629 | 0.76 | TSHR (0.47) | GGPS1FDPS | |
| Ammonia Solution, Strong SCHEMBL11212815 | 0.76 | TSHR (0.47) | GGPS1FDPS | |
| Phosphine SCHEMBL1535966 | 0.76 | TSHR (0.47) | GGPS1FDPS | |
| Ammonia Solution, Strong SCHEMBL1697449 | 0.76 | TSHR (0.47) | GGPS1FDPS | |
| Phosphine SCHEMBL10694267 | 0.76 | TSHR (0.47) | GGPS1FDPS | |
| SCHEMBL4455057 | 0.76 | LPAR3 (0.50) | LPAR3LPAR2GGPS1FDPSS1PR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010056074-A1 | Novel lipophilic compounds having affinity with nucleic acids and therapeutical uses thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIOUE CNPS (FR) | 2001-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056074-A1 | Novel lipophilic compounds having affinity with nucleic acids and therapeutical uses thereof | RNASEH1, SLC67A1, HNRNPA1 | LPAR3 162/4885LPAR2 267/4885GGPS1 2434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.